69 related articles for article (PubMed ID: 19932710)
1. Follow-up for cervical abnormalities in a managed care plan, 1999-2004.
Benard VB; Berkman ND; Kuo T; Martin CK; Richardson LC
Prev Med; 2010; 50(1-2):81-5. PubMed ID: 19932710
[TBL] [Abstract][Full Text] [Related]
2. Assessment of follow-up for low-grade cytological abnormalities in the National Breast and Cervical Cancer Early Detection Program, 2000-2005.
Benard VB; Howe W; Saraiya M; Helsel W; Lawson HW
J Low Genit Tract Dis; 2008 Oct; 12(4):300-6. PubMed ID: 18820545
[TBL] [Abstract][Full Text] [Related]
3. What predicts adherence to follow-up recommendations for abnormal Pap tests among older women?
Coker AL; Eggleston KS; Meyer TE; Luchok K; Das IP
Gynecol Oncol; 2007 Apr; 105(1):74-80. PubMed ID: 17157363
[TBL] [Abstract][Full Text] [Related]
4. Adherence characteristics after abnormal screening results between mammogram and Papanicolaou test groups.
Fang SY; Shu BC
Cancer Nurs; 2009; 32(6):437-45. PubMed ID: 19816157
[TBL] [Abstract][Full Text] [Related]
5. Follow-up Papanicolaou smear for cervical atypia: are we missing significant disease? A HARNET Study.
Slawson DC; Bennett JH; Herman JM
J Fam Pract; 1993 Mar; 36(3):289-93. PubMed ID: 8454975
[TBL] [Abstract][Full Text] [Related]
6. ASCCP patient management guidelines: Pap test specimen adequacy and quality indicators.
Davey DD; Austin RM; Birdsong G; Buck HW; Cox JT; Darragh TM; Elgert PA; Hanson V; Henry MR; Waldman J;
Am J Clin Pathol; 2002 Nov; 118(5):714-8. PubMed ID: 12428791
[TBL] [Abstract][Full Text] [Related]
7. [Follow up after an abnormal pap smear: time interval acceptable, nature of follow up leaves room for improvement].
Geertsen M; Bais AG; Beerman H; Helmerhorst TJ
Ned Tijdschr Geneeskd; 2003 Dec; 147(49):2430-4. PubMed ID: 14694554
[TBL] [Abstract][Full Text] [Related]
8. [Evaluation of the follow-up of women aged 50-74 years after cervical cytological Ascus abnormalities in cancer screening: adherence to clinical practice guidelines in Isere, France; 1991-2000].
Billette-de-Villemeur A; Poncet F; Garnier A; Marron J; Le Marc'hadour F; Morens A; Rouault-Plantaz V; Ney M; Exbrayat C
Gynecol Obstet Fertil; 2009 Oct; 37(10):787-95. PubMed ID: 19782628
[TBL] [Abstract][Full Text] [Related]
9. [Less pap-2 results ('minor abnormalities') in the population screening for cervical cancer since the introduction of new guidelines in 1996].
Bos AB; van Ballegooijen M; van den Akker-van Marle ME; Habbema JD
Ned Tijdschr Geneeskd; 2002 Aug; 146(34):1586-90. PubMed ID: 12224483
[TBL] [Abstract][Full Text] [Related]
10. Cervical cancer in women with comprehensive health care access: attributable factors in the screening process.
Leyden WA; Manos MM; Geiger AM; Weinmann S; Mouchawar J; Bischoff K; Yood MU; Gilbert J; Taplin SH
J Natl Cancer Inst; 2005 May; 97(9):675-83. PubMed ID: 15870438
[TBL] [Abstract][Full Text] [Related]
11. Cervicography: adjunctive cervical cancer screening by primary care clinicians.
Ferris DG; Payne P; Frisch LE; Milner FH; diPaola FM; Petry LJ
J Fam Pract; 1993 Aug; 37(2):158-64. PubMed ID: 8336097
[TBL] [Abstract][Full Text] [Related]
12. Early detection of precursors of cervical cancer with cervical cytology and visual inspection of cervix with acetic Acid.
Dhaubhadel P; Vaidya A; Choudhary P
JNMA J Nepal Med Assoc; 2008; 47(170):71-6. PubMed ID: 18709035
[TBL] [Abstract][Full Text] [Related]
13. Comparison of visual inspection and Papanicolau (PAP) smears for cervical cancer screening in Honduras: should PAP smears be abandoned?
Perkins RB; Langrish SM; Stern LJ; Figueroa J; Simon CJ
Trop Med Int Health; 2007 Sep; 12(9):1018-25. PubMed ID: 17875013
[TBL] [Abstract][Full Text] [Related]
14. Clinical evaluation of follow-up methods and results of atypical glandular cells of undetermined significance (AGUS) detected on cervicovaginal Pap smears.
Kim TJ; Kim HS; Park CT; Park IS; Hong SR; Park JS; Shim JU
Gynecol Oncol; 1999 May; 73(2):292-8. PubMed ID: 10329049
[TBL] [Abstract][Full Text] [Related]
15. Adjunctive high-risk human papillomavirus DNA testing is a useful option for disease risk assessment in patients with negative Papanicolaou tests without an endocervical/transformation zone sample.
Zhao C; Austin RM
Cancer; 2008 Aug; 114(4):242-8. PubMed ID: 18484643
[TBL] [Abstract][Full Text] [Related]
16. Predictors of follow-up of atypical and ASCUS papanicolaou tests in a high-risk population.
McKee MD; Schechter C; Burton W; Mulvihill M
J Fam Pract; 2001 Jul; 50(7):609. PubMed ID: 11485710
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of visual inspection with acetic acid (VIA), Lugol's iodine (VILI), cervical cytology and HPV testing as cervical screening tools in Latin America. This report refers to partial results from the LAMS (Latin AMerican Screening) study.
Sarian LO; Derchain SF; Naud P; Roteli-Martins C; Longatto-Filho A; Tatti S; Branca M; Erzen M; Serpa-Hammes L; Matos J; Gontijo R; Bragança JF; Lima TP; Maeda MY; Lörincz A; Dores GB; Costa S; Syrjänen S; Syrjänen K
J Med Screen; 2005; 12(3):142-9. PubMed ID: 16156945
[TBL] [Abstract][Full Text] [Related]
18. [Follow-up not according to guidelines after an abnormal cervix smear].
Kreuger FA; Beerman H; Nijs HG; Wijnen JA
Ned Tijdschr Geneeskd; 1996 Apr; 140(15):833-6. PubMed ID: 8668277
[TBL] [Abstract][Full Text] [Related]
19. Assessment of cytologic follow-up as the recommended management for patients with atypical squamous cells of undetermined significance or low grade squamous intraepithelial lesions.
Alanen KW; Elit LM; Molinaro PA; McLachlin CM
Cancer; 1998 Feb; 84(1):5-10. PubMed ID: 9500646
[TBL] [Abstract][Full Text] [Related]
20. Screening for cervical disease in mature women: strategies for improvement.
Colgan TJ; Clarke A; Hakh N; Seidenfeld A
Cancer; 2002 Aug; 96(4):195-203. PubMed ID: 12209660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
